We have built an effective hybrid discovery approach, alternating in vitro with in silico steps. This allows us and our clients, the maximum exploitation of biologically/clinically relevant information. We deliver highly performing, mature and feasible solutions to be readily translated to bench top diagnostics and drive fast drug discovery. Our strength lies in bridging disciplines, in our highly specialised team, with years of research and development in biomarker and drug target discovery.
Join us as we develop a better future for healthcare.
Novel Drug Target Discovery
Building a disruptive diagnostic method for diabetes
Prof. Ekaterini Alexiou-Chatzaki,
CEO & coFounder at ABCureD
Using AI/ML to Accelerate Innovation in Biomedicine
Biomarker and Drug Target Discovery
is Slow and Expensive
Most conditions are still poorly treated, with low therapeutic response rates. Whether it’s cancer, metabolic, neurodegenerative or immune diseases, there is a faster and less expensive way to reach better outcomes. ABCureD accelerates and optimizes the roadmap from research lab to clinic. We thrive on the momentum, transition from hypothesis-driven to big-data-driven development. Artificial Intelligence is changing the way we conduct R&D in biomedicine.
% = Non-respondents to treatment. Low therapeutic rate.
Prof. Ekaterini Chatzaki, CEO and coFounder of ABCURED, was interviewed by Maria Moschou for the Greek online media EURO2day regarding the recent first award received at the NBG (National Bank